INR 544.6
(-1.37%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 4.02 Billion INR | -6.73% |
2022 | 4.31 Billion INR | -53.98% |
2021 | 9.36 Billion INR | -33.59% |
2020 | 14.1 Billion INR | 18.08% |
2019 | 11.94 Billion INR | 16.19% |
2018 | 10.28 Billion INR | -21.02% |
2017 | 13.01 Billion INR | -11.12% |
2016 | 14.64 Billion INR | 4.27% |
2015 | 14.04 Billion INR | -3.51% |
2014 | 14.55 Billion INR | 2.15% |
2013 | 14.25 Billion INR | 18.13% |
2012 | 12.06 Billion INR | 7.34% |
2011 | 11.23 Billion INR | 4.21% |
2010 | 10.78 Billion INR | 10.04% |
2009 | 9.8 Billion INR | -10.23% |
2008 | 10.91 Billion INR | 80.84% |
2007 | 6.03 Billion INR | 21.67% |
2006 | 4.96 Billion INR | -35.12% |
2005 | 7.64 Billion INR | 195.24% |
2004 | 2.59 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -8.38 Billion INR | -308.5% |
2023 Q2 | 4.28 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2023 FY | 4.02 Billion INR | -6.73% |
2023 Q4 | 4.02 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2022 FY | 4.31 Billion INR | -53.98% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 5.45 Billion INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 4.31 Billion INR | 0.0% |
2021 Q4 | 9.36 Billion INR | 0.0% |
2021 Q2 | 15.89 Billion INR | 0.0% |
2021 FY | 9.36 Billion INR | -33.59% |
2021 Q1 | - INR | -100.0% |
2021 Q3 | - INR | -100.0% |
2020 FY | 14.1 Billion INR | 18.08% |
2020 Q2 | 12.77 Billion INR | 0.0% |
2020 Q4 | 14.1 Billion INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2019 Q4 | 11.94 Billion INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 Q2 | 11.49 Billion INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 FY | 11.94 Billion INR | 16.19% |
2018 Q4 | 10.28 Billion INR | 0.0% |
2018 FY | 10.28 Billion INR | -21.02% |
2017 FY | 13.01 Billion INR | -11.12% |
2016 FY | 14.64 Billion INR | 4.27% |
2015 FY | 14.04 Billion INR | -3.51% |
2014 FY | 14.55 Billion INR | 2.15% |
2013 FY | 14.25 Billion INR | 18.13% |
2012 FY | 12.06 Billion INR | 7.34% |
2011 FY | 11.23 Billion INR | 4.21% |
2010 FY | 10.78 Billion INR | 10.04% |
2009 FY | 9.8 Billion INR | -10.23% |
2008 FY | 10.91 Billion INR | 80.84% |
2007 FY | 6.03 Billion INR | 21.67% |
2006 FY | 4.96 Billion INR | -35.12% |
2005 FY | 7.64 Billion INR | 195.24% |
2004 FY | 2.59 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Biocon Limited | 307.95 Billion INR | 98.695% |
Blue Jet Healthcare Limited | 2.13 Billion INR | -88.191% |
Concord Biotech Limited | 1.74 Billion INR | -130.962% |
Dishman Carbogen Amcis Limited | 39.53 Billion INR | 89.832% |
Jubilant Ingrevia Limited | 19.94 Billion INR | 79.843% |
Lyka Labs Limited | 884.58 Million INR | -354.472% |
Piramal Pharma Limited | 74 Billion INR | 94.568% |
SMS Lifesciences India Limited | 1.96 Billion INR | -104.193% |
Supriya Lifescience Limited | 1.05 Billion INR | -279.73% |
Syngene International Limited | 18.93 Billion INR | 78.773% |
TAKE Solutions Limited | 969.78 Million INR | -314.548% |
Zota Health Care Limited | 1.38 Billion INR | -190.578% |